Brokerages Set ADMA Biologics, Inc. (NASDAQ:ADMA) Price Target at $7.88

Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) have earned an average recommendation of “Buy” from the four analysts that are presently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $7.88.

Several research analysts recently commented on ADMA shares. Cantor Fitzgerald raised their price target on shares of ADMA Biologics from $6.50 to $8.00 and gave the company an “overweight” rating in a report on Thursday, February 29th. Mizuho lifted their target price on shares of ADMA Biologics from $9.00 to $10.00 and gave the company a “buy” rating in a report on Friday, March 1st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $7.50 price target (up from $6.00) on shares of ADMA Biologics in a research report on Tuesday, March 26th.

ADMA Biologics Stock Performance

NASDAQ:ADMA opened at $6.81 on Wednesday. The company has a market cap of $1.55 billion, a P/E ratio of -52.38 and a beta of 0.43. The firm’s 50 day moving average is $6.21 and its two-hundred day moving average is $5.01. ADMA Biologics has a fifty-two week low of $3.06 and a fifty-two week high of $6.81. The company has a quick ratio of 1.69, a current ratio of 5.16 and a debt-to-equity ratio of 1.04.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, February 28th. The biotechnology company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.02. The firm had revenue of $73.90 million for the quarter, compared to analysts’ expectations of $73.50 million. ADMA Biologics had a positive return on equity of 0.49% and a negative net margin of 10.94%. Analysts expect that ADMA Biologics will post 0.3 EPS for the current year.

Insider Activity

In other ADMA Biologics news, Director Steve Elms sold 183,008 shares of the business’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $6.01, for a total value of $1,099,878.08. Following the transaction, the director now owns 2,577,387 shares in the company, valued at approximately $15,490,095.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders sold 639,895 shares of company stock worth $3,927,169. 6.00% of the stock is currently owned by company insiders.

Institutional Trading of ADMA Biologics

A number of hedge funds and other institutional investors have recently made changes to their positions in ADMA. Rice Hall James & Associates LLC acquired a new position in ADMA Biologics in the first quarter worth about $7,963,000. Charles Schwab Investment Management Inc. lifted its stake in ADMA Biologics by 182.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,609,346 shares of the biotechnology company’s stock valued at $5,761,000 after buying an additional 1,039,893 shares during the last quarter. Walleye Capital LLC acquired a new position in shares of ADMA Biologics during the third quarter valued at $3,318,000. Peregrine Capital Management LLC bought a new position in shares of ADMA Biologics during the fourth quarter worth about $3,991,000. Finally, American Century Companies Inc. increased its holdings in shares of ADMA Biologics by 20.8% in the 3rd quarter. American Century Companies Inc. now owns 4,892,123 shares of the biotechnology company’s stock worth $17,514,000 after acquiring an additional 840,761 shares during the period. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.